Announcements Trials
Browse Landscape

Status

Completed 3Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER_GOV 1OTHER 1

Study Type

Interventional 66Observational 7

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 2Stomach Neoplasms 1Resectable Non-small Cell Lung Cancer 1Pancreatic Neoplasms 1Liver Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Observational × Platinum Compounds × Clear all
NCT05363319 2026-05-13

CEMI-LUNG

Regeneron Pharmaceuticals

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Bristol-Myers Squibb

Completed
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Bristol-Myers Squibb

Active not recruiting
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06169956 2024-04-18

NENI

Bristol-Myers Squibb

Recruiting
400 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Yuhan Corporation

Completed
534 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05569668 2022-10-06

Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma

Henan Cancer Hospital

Completed
826 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03668418 2018-09-12

xenoZ

University of Pisa

Unknown
120 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡